Clinical Biomarkers

Funding to identify and implement molecular testing for those affected by a brain tumour.

Purpose and scope

This scheme supports the identification, validation, and implementation of clinical biomarkers into clinical use and bring us closer to an early and accurate diagnosis. Studies may make use of the samples and infrastructure brought about by funded clinical trials, to go beyond the primary and secondary endpoints and generate new knowledge around clinical biomarkers.


Guide costs: up to £100,000 per year for up to five years.

Funding is intended to allow the production of new insights (e.g. identification of new biomarkers or further stratification of the trial population) which will lead us to early and accurate diagnosis. This funding should be primarily allocated to cover direct costs of consumables, and additional Full-Time Equivalent costs where appropriate justification is made. Requests for capital /infrastructure will not be considered since it is expected that this will be available at the Lead Institution as well as all partner organisations.

Grants will be awarded to the principal applicant's institution. Funding can be allocated to co-investigator institutions with agreements put in place between all partner institutions.

Eligibility criteria

  • All grant applications must address the issue of earlier and accurate diagnosis, as highlighted in our research strategy 'A Cure Can't Wait'
  • This award is open to international researchers but all proposals must demonstrate how they can benefit patients in the UK health system
  • Applications MUST include a clinical AND a scientific lead
  • Proposals that make use of the infrastructure and/or samples, already in use for a funded trial, are strongly encouraged
  • If proposals are submitted in the context of an already funded clinical trial, the funding obtained may not be used for the purposes of achieving the primary or second endpoints of the trial as this should be covered by the initial funding. Funding is intended to allow the production of new insights (e.g. identification of new biomarkers or further stratification of the trial population), which will lead to early and accurate diagnosis.

Please read our Grant Conditions, Finance Guidelines, and Data Protection Statement before applying for funding..

Public and patient involvement

All applications must have input from those affected by brain tumours as early as possible, preferably during scoping of the project. We strongly recommend that applicants access our Research Involvement Network (RIN) for public and patient involvement. In order to receive feedback from the RIN, please allow for a minimum of 3 weeks turnaround time.

Key Dates

Applications are now closed and will reopen next year.

Assessment criteria


  • Projects must have a sound approach and methodology in order to address the questions raised

Statistical validity

  • Projects must be statistically powered so results are significant and meaningful

Expertise of applicants

  • The applicants must be appropriately trained and well suited to carry out the planned studies

Potential for patient benefit

  • Projects must articulate a clear pathway leading to patient benefit as well as the anticipated impact and likelihood of achieving an early and accurate diagnosis
  • Applications with a clear path to clinical or practical application will be strongly favoured
  • Applicants must demonstrate how their findings will be taken up and funded by the NHS following The Charity's investment

Value for money

  • Projects must demonstrate that the funds requested are essential for the work and how these represent value for money

The Brain Tumour Charity is a member of the Association of Medical Research Charities (AMRC) and adheres to its principles of peer review. Applications will be awarded through a competitive peer reviewed process (in line with AMRC principles) and then considered by our Scientific Advisory Boards (SABs).

Further information

If you would like to discuss project ideas or need any information, please contact the Research Team.
Phone: +44 (0) 1252 418190

We promise to keep your data safe and you can unsubscribe at any time in the future. More information is in our Privacy Policy.